Hyperion brings in $13M for gastrointestinal relief
Hyperion Therapeutics, maker of pharmaceuticals to treat hepatology and gastrointenstinal conditions, has raised $13 million of an anticipated $15 million round of debt, according to VentureWire. Contributors have not been disclosed, but the South San Francisco, Calif. company had previously raked in $40 million in a second round of funding from Sofinnova Ventures, Highland Capital Partners, New Enterprise Associates and Washington Research Foundation Capital.
Hyperion is one of the companies that has reported fundraising activity due to new Form D requirements that companies notify the government within 15 days after the sale of securities in an offering.
Next Story: Renewable Fuel Products takes $145K to turn veggie oil into fuel
Previous Story: UserVoice raises $800K for customer feedback systems
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.